Alimera Sciences, Inc. , a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, and Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, today announced that Knight’s New Drug Submission for ILUVIEN has been accepted for review by Health Canada. ILUVIEN 0.19 mg is Alimera’s sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.